Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Not yet recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Recurrence 1Lymphoma, T-Cell, Cutaneous 1Leukemia, Myeloid, Acute 1

Interventions

pembrolizumab 78Cyclophosphamide 55Specimen Handling 53Carboplatin 49fludarabine 44Nivolumab 42Magnetic Resonance Spectroscopy 42Gemcitabine 37Biopsy 37Bevacizumab 34Dexamethasone 31venetoclax 27Paclitaxel 26Injections 25Docetaxel 25atezolizumab 24Cisplatin 24Pemetrexed 23Ipilimumab 22Capecitabine 21Temozolomide 19abemaciclib 18Rituximab 18Oxaliplatin 18Lenalidomide 18Fulvestrant 18Cetuximab 18Azacitidine 17Vincristine 15Fluorouracil 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Aclarubicin × 90 days × Clear all
NCT07535710 2026-04-17

Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
37 enrolled
DermatologicLymphoid

Recurrence, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT07486726 2026-03-20

Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia

Shanghai Jiao Tong University School of Medicine

Phase 1/2 Not yet recruiting
112 enrolled
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡